190 related articles for article (PubMed ID: 31600525)
21. Pharmacokinetic variability of anthelmintics: implications for the treatment of neurocysticercosis.
Jung-Cook H
Expert Rev Clin Pharmacol; 2012 Jan; 5(1):21-30. PubMed ID: 22142156
[TBL] [Abstract][Full Text] [Related]
22. Effect of dexamethasone on albendazole cysticidal activity in experimental cysticercosis by Taenia crassiceps in BALB/c mice: In vitro and in vivo evaluation.
Palomares-Alonso F; Toledo A; Palencia Hernández G; Jung-Cook H; Fleury A
Exp Parasitol; 2020 Jan; 208():107801. PubMed ID: 31730781
[TBL] [Abstract][Full Text] [Related]
23. Novel albendazole-chitosan nanoparticles for intestinal absorption enhancement and hepatic targeting improvement in rats.
Liu Y; Wang XQ; Ren WX; Chen YL; Yu Y; Zhang JK; Bawudong D; Gu JP; Xu XD; Zhang XN
J Biomed Mater Res B Appl Biomater; 2013 Aug; 101(6):998-1005. PubMed ID: 23529958
[TBL] [Abstract][Full Text] [Related]
24. Albendazole versus ricobendazole (albendazole-sulphoxide) against enteral and parenteral stages of Trichinella spiralis in mice.
Lopez-Garcia ML; Torrado-Duran S; Torrado-Duran J; Martínez-Fernández AR; Bolás-Fernández F
Int J Parasitol; 1997 Jul; 27(7):781-5. PubMed ID: 9279580
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the interaction between ivermectin and albendazole following their combined use in lambs.
Alvarez L; Lifschitz A; Entrocasso C; Manazza J; Mottier L; Borda B; Virkel G; Lanusse C
J Vet Pharmacol Ther; 2008 Jun; 31(3):230-9. PubMed ID: 18471144
[TBL] [Abstract][Full Text] [Related]
26. Methimazole-mediated enhancement of albendazole oral bioavailability and anthelmintic effects against parenteral stages of Trichinella spiralis in mice: the influence of the dose-regime.
López-García ML; Torrado S; Torrado S; Martínez AR; Bolás F
Vet Parasitol; 1998 Feb; 75(2-3):209-19. PubMed ID: 9637222
[TBL] [Abstract][Full Text] [Related]
27. Uptake of albendazole and albendazole sulphoxide by Haemonchus contortus and Fasciola hepatica in sheep.
Alvarez LI; Imperiale FA; Sánchez SF; Murno GA; Lanusse CE
Vet Parasitol; 2000 Dec; 94(1-2):75-89. PubMed ID: 11078946
[TBL] [Abstract][Full Text] [Related]
28. Fasting-induced changes to the pharmacokinetic behaviour of albendazole and its metabolites in calves.
Sánchez SF; Alvarez LI; Lanusse CE
J Vet Pharmacol Ther; 1997 Feb; 20(1):38-47. PubMed ID: 9049948
[TBL] [Abstract][Full Text] [Related]
29. Improving bioavailability and anthelmintic activity of albendazole by preparing albendazole-cyclodextrin complexes.
García-Rodriguez JJ; Torrado J; Bolás F
Parasite; 2001 Jun; 8(2 Suppl):S188-90. PubMed ID: 11484352
[TBL] [Abstract][Full Text] [Related]
30. In vivo and ex vivo uptake of albendazole and its sulphoxide metabolite by cestode parasites: relationship with their kinetic behaviour in sheep.
Alvarez LI; Sánchez SF; Lanusse CE
J Vet Pharmacol Ther; 1999 Apr; 22(2):77-86. PubMed ID: 10372592
[TBL] [Abstract][Full Text] [Related]
31. Bioavailability comparison between albendazole and albendazole sulphoxide in rats and man.
Dominguez L; Fagiolino P; Gordon S; Manta E
Farmaco; 1995 Oct; 50(10):697-702. PubMed ID: 8590577
[TBL] [Abstract][Full Text] [Related]
32. In vivo effect of oral albendazole and albendazole sulphoxide on development of secondary echinococcosis in mice.
Pérez-Serrano J; Denegri G; Casado N; Rodríguez-Caabeiro F
Int J Parasitol; 1997 Nov; 27(11):1341-5. PubMed ID: 9421721
[TBL] [Abstract][Full Text] [Related]
33. Histopathologic evaluation of experimental murine neurocysticercosis after treatment with albendazole/nitazoxanide combination.
Sampaio GA; Zago LV; de Lima NF; Picanço GA; Lino Júnior RS; Vinaud MC
Parasitology; 2020 Jun; 147(7):822-827. PubMed ID: 32234089
[TBL] [Abstract][Full Text] [Related]
34. Oxfendazole induces protein catabolism and gluconeogenesis in experimental neurocysticercosis.
Correia LTB; de Lima NF; Gomes TC; De Sousa Guerra CH; Costa TL; Vinaud MC
Acta Trop; 2022 Oct; 234():106571. PubMed ID: 35752205
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis.
Pourgholami MH; Akhter J; Wang L; Lu Y; Morris DL
Cancer Chemother Pharmacol; 2005 May; 55(5):425-32. PubMed ID: 15565325
[TBL] [Abstract][Full Text] [Related]
36. Effect of amphiphilic surfactant agents on the gastrointestinal absorption of albendazole in cattle.
Virkel G; Imperiale F; Lifschitz A; Pis A; Alvarez A; Merino G; Prieto J; Lanusse C
Biopharm Drug Dispos; 2003 Apr; 24(3):95-103. PubMed ID: 12673667
[TBL] [Abstract][Full Text] [Related]
37. Dose-dependent systemic exposure of albendazole metabolites in lambs.
Alvarez L; Suárez G; Ceballos L; Moreno L; Lanusse C
J Vet Pharmacol Ther; 2012 Aug; 35(4):365-72. PubMed ID: 21819410
[TBL] [Abstract][Full Text] [Related]
38. A case from India of neurocysticercosis responsive to albendazole treatment.
Zardi EM; Petrarca V; Pozio E; Uwechie V; Tamburrini A; Laghi V
Parasite; 2000 Mar; 7(1):54-6. PubMed ID: 10743650
[No Abstract] [Full Text] [Related]
39. Albendazole-loaded cubosomes interrupt the ERK1/2-HIF-1α-p300/CREB axis in mice intoxicated with diethylnitrosamine: A new paradigm in drug repurposing for the inhibition of hepatocellular carcinoma progression.
Saber S; Nasr M; Saad AS; Mourad AAE; Gobba NA; Shata A; Hafez AM; Elsergany RN; Elagamy HI; El-Ahwany E; Amin NA; Girgis S; Elewa YHA; Mahmoud MH; Batiha GE; El-Rous MA; Kamal I; Kaddah MMY; Khodir AE
Biomed Pharmacother; 2021 Oct; 142():112029. PubMed ID: 34416629
[TBL] [Abstract][Full Text] [Related]
40. Assessment of serum pharmacokinetics and urinary excretion of albendazole and its metabolites in human volunteers.
Ceballos L; Krolewiecki A; Juárez M; Moreno L; Schaer F; Alvarez LI; Cimino R; Walson J; Lanusse CE
PLoS Negl Trop Dis; 2018 Jan; 12(1):e0005945. PubMed ID: 29346367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
